-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Telesis Bio, Inc. (NASDAQ:DNAY) Short Interest Up 12.3% in October
Telesis Bio, Inc. (NASDAQ:DNAY) Short Interest Up 12.3% in October
Telesis Bio, Inc. (NASDAQ:DNAY) was the recipient of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 265,400 shares, an increase of 12.3% from the October 15th total of 236,300 shares. Approximately 3.1% of the company's shares are sold short. Based on an average daily volume of 108,600 shares, the days-to-cover ratio is currently 2.4 days.
Telesis Bio Price Performance
Shares of Telesis Bio stock remained flat at $1.67 on Wednesday. The stock had a trading volume of 40,058 shares, compared to its average volume of 340,929. The firm's 50-day simple moving average is $1.76 and its 200-day simple moving average is $2.35. Telesis Bio has a 12-month low of $1.38 and a 12-month high of $11.32. The company has a current ratio of 4.86, a quick ratio of 4.68 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $49.30 million, a price-to-earnings ratio of -0.93 and a beta of 1.45.
Get Telesis Bio alerts:
Telesis Bio (NASDAQ:DNAY – Get Rating) last posted its quarterly earnings data on Tuesday, November 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.06. The company had revenue of $6.68 million during the quarter, compared to analysts' expectations of $5.30 million. Telesis Bio had a negative return on equity of 73.65% and a negative net margin of 251.04%. As a group, analysts anticipate that Telesis Bio will post -1.85 EPS for the current year.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. Penbrook Management LLC increased its position in Telesis Bio by 44.3% during the 3rd quarter. Penbrook Management LLC now owns 268,850 shares of the company's stock valued at $446,000 after buying an additional 82,560 shares in the last quarter. Penn Capital Management Company LLC acquired a new position in Telesis Bio during the 2nd quarter valued at about $944,000. Millennium Management LLC grew its stake in Telesis Bio by 73.3% during the 2nd quarter. Millennium Management LLC now owns 433,622 shares of the company's stock valued at $781,000 after purchasing an additional 183,440 shares during the last quarter. Bank of America Corp DE grew its stake in Telesis Bio by 696.7% during the 1st quarter. Bank of America Corp DE now owns 43,454 shares of the company's stock valued at $233,000 after purchasing an additional 38,000 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in Telesis Bio by 563.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 154,539 shares of the company's stock valued at $830,000 after purchasing an additional 131,243 shares during the last quarter. 49.13% of the stock is owned by institutional investors.
Analyst Ratings Changes
Separately, KeyCorp dropped their target price on Telesis Bio from $8.00 to $5.00 and set an "overweight" rating for the company in a report on Wednesday, November 9th.
Telesis Bio Company Profile
(Get Rating)
Codex DNA, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis.
Recommended Stories
Get a free copy of the StockNews.com research report on Telesis Bio (DNAY)
Why Lowe's Is Up And Home Depot Down
The TJX Companies Could Break Out To New Highs
Gold Rush: Newmont Corp. is Starting to Sparkle
Four Healthcare Stocks To Watch This Week
Will It Be Smooth Sailing For Carnival After 56% One-Month Rally?
Receive News & Ratings for Telesis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telesis Bio and related companies with MarketBeat.com's FREE daily email newsletter.
Telesis Bio,Inc.(纳斯达克代码:DNAY)是10月份空头股数大幅增长的接收方。截至10月31日,空头股数共有26.54万股,比10月15日的23.63万股增加了12.3%。该公司约3.1%的股票被卖空。根据日均成交量108,600股计算,目前天数与回补比率为2.4天。
Telesis生物性价比
周三,Telesis Bio的股价持平于1.67美元。该股成交量为40,058股,而其平均成交量为340,929股。该公司的50日简单移动均线切入位为1.76美元,200日简单移动均线切入位为2.35美元。Telesis Bio的12个月低点为1.38美元,12个月高位为11.32美元。该公司的流动比率为4.86,速动比率为4.68,债务权益比率为0.37。该公司的市值为4930万美元,市盈率为-0.93倍,贝塔系数为1.45。
到达Telesis Bio警报:
Telesis Bio(纳斯达克代码:DNAY-GET Rating)最近一次公布季度收益数据是在11月8日星期二。该公司公布本季度每股收益(EPS)为0.42美元,比分析师普遍预期的0.48美元高出0.06美元。该公司本季度营收为668万美元,高于分析师预期的530万美元。Telesis Bio的股本回报率为负73.65%,净利润率为负251.04%。作为一个整体,分析师预计Telesis Bio今年的每股收益将达到1.85欧元。
机构资金流入和流出
大型投资者最近对他们在该股的头寸进行了调整。Penbrook Management LLC在第三季度将其在Telesis Bio的头寸增加了44.3%。Penbrook Management LLC现在拥有268,850股该公司股票,价值446,000美元,上个季度又购买了82,560股。宾夕法尼亚资本管理公司在第二季度收购了Telesis Bio的一个新头寸,价值约94.4万美元。千禧管理公司在第二季度持有的Telesis Bio股份增加了73.3%。Millennium Management LLC在上个季度额外购买了183,440股后,现在拥有433,622股该公司的股票,价值78.1万美元。第一季度,美国银行DE在Telesis Bio的持股增加了696.7%。美国银行DE目前持有43,454股该公司股票,价值23.3万美元,此前该公司在上一季度又购买了3.8万股。最后,高盛股份有限公司在第一季度增持了563.4%的Telesis Bio股份。高盛股份有限公司在上个季度增持了131,243股后,目前持有154,539股该公司股票,价值830,000美元。49.13%的股份由机构投资者持有。
分析师评级发生变化
另外,KeyCorp在11月9日周三的一份报告中将Telesis Bio的目标价从8.00美元下调至5.00美元,并为该公司设定了“增持”评级。
Telesis Bio公司简介
(获取评级)
Codex DNA公司是一家合成生物学公司,主要向世界各地的制药和学术实验室制造和销售合成生物学仪器、试剂和相关产品及相关服务。它的解决方案包括BioXp系统,它使研究人员能够从数字DNA序列过渡到终端就绪的合成DNA;BioXp门户网站,它提供了直观的指导工作流程和设计工具,用于构建新的DNA序列并将其组装成选择的载体;BioXp试剂盒,其中包含用于特定合成生物学工作流程应用的构建块和试剂,包括其Gibson Assembly品牌试剂;基于云的脚本;Benchtop试剂,包含使用BioXp系统生成的产品在桌面上进行特定合成生物学工作流程所需的所有试剂;Biofoundry服务,使客户能够订购和接收BioXp系统终端就绪型产品,如基因、克隆、无细胞扩增DNA和变异库;以及短寡聚连接组装酶DNA合成。
推荐故事
免费获取StockNews.com关于Telesis Bio的研究报告(DNAY)
为什么Lowe‘s上升,Home Depot下降
TJX公司可能突破新高
淘金热:纽蒙特公司开始闪耀光芒
本周值得关注的四只医疗保健类股
经过一个月56%的涨势,狂欢节会一帆风顺吗?
接受Telesis Bio Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Telesis Bio和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧